PFE vs. JNJ, MRK, ABBV, BMY, ZTS, RPRX, JAZZ, PRGO, CORT, and SUPN
Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.
Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and community ranking.
In the previous week, Johnson & Johnson had 5 more articles in the media than Pfizer. MarketBeat recorded 52 mentions for Johnson & Johnson and 47 mentions for Pfizer. Johnson & Johnson's average media sentiment score of 0.65 beat Pfizer's score of 0.33 indicating that Pfizer is being referred to more favorably in the news media.
Johnson & Johnson has a net margin of 46.34% compared to Johnson & Johnson's net margin of -0.56%. Pfizer's return on equity of 36.79% beat Johnson & Johnson's return on equity.
Johnson & Johnson has higher revenue and earnings than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.
Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.1%. Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 5.5%. Johnson & Johnson pays out 30.9% of its earnings in the form of a dividend. Pfizer pays out -2,799.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has increased its dividend for 63 consecutive years and Pfizer has increased its dividend for 15 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and lower payout ratio.
Johnson & Johnson presently has a consensus target price of $173.00, indicating a potential upside of 7.67%. Pfizer has a consensus target price of $34.50, indicating a potential upside of 12.12%. Given Johnson & Johnson's higher possible upside, analysts plainly believe Pfizer is more favorable than Johnson & Johnson.
Johnson & Johnson has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.
69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by insiders. Comparatively, 0.1% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Pfizer received 398 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 69.07% of users gave Pfizer an outperform vote while only 64.89% of users gave Johnson & Johnson an outperform vote.
Summary
Johnson & Johnson beats Pfizer on 14 of the 21 factors compared between the two stocks.
Get Pfizer News Delivered to You Automatically
Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
Free PFE Stock Alerts